文献速递眼底病与葡萄膜炎

采用离散选择实验验证新型糖尿病视网膜病变效用指数

Validation of a novel diabetic retinopathy utility index using discrete choice experiments.
PubMed 文献 · Br J Ophthalmol · 2019-05-16

本研究采用离散选择实验(DCE)方法验证糖尿病视网膜病变效用指数(DRU-I),并评估威胁视力糖尿病视网膜病变(VTDR)及相关视力损害对应的负效用。研究纳入220例参与者(平均年龄60.1±11.3岁,70.9%为男性),其中VTDR 139例(70.9%)、非VTDR 57例(29.1%)。DRU-I效用值随DR严重程度(非VTDR=0.87 vs VTDR=0.80,p=0.021)及较好眼视力损害程度(无=0.84、轻度=0.78、中/重度=0.72,p=0.012)加重而下降。

要点

  • DRU-I包含五个生活质量维度:视觉症状、活动受限/移动、光线与眩光、社会情绪健康及不便程度。
  • DRU-I效用值随DR严重程度加重而下降:非VTDR=0.87 vs VTDR=0.80(p=0.021)。
  • DRU-I效用值与EQ-5D相关性低(r=0.39),与VisQoL相关性中等(r=0.58)。

核心结论

  • DRU-I能够估算威胁视力糖尿病视网膜病变及相关视力损害对应的效用值。
  • DRU-I有潜力从患者角度评估DR干预的成本效果,并为DR相关资源配置政策提供信息。

研究设计与样本

  • 本研究为采用离散选择实验(DCE)方法验证偏好为基础的糖尿病视网膜病变效用指数(DRU-I)的研究。
  • DRU-I包含五个生活质量维度,每个维度按无、一些或很多困难进行评级。
  • DCE包含六个区组,每个区组九个选择集,与EuroQoL-5D(EQ-5D-3L)及视力和生活质量(VisQoL)效用工具一同由访问员施测。
  • 为确保DRU-I对严重疾病敏感,研究过采样了VTDR患者。
  • 共纳入220例参与者(平均±标准差年龄60.1±11.3岁;70.9%为男性)。

主要发现

  • 57例(29.1%)为非VTDR,139例(70.9%)为VTDR。
  • 157例(71.4%)无视力损害,20例(9.4%)为轻度视力损害,37例(17.3%)为中/重度视力损害。
  • 所有维度的回归系数排序符合预期,各维度水平越差越不被偏好(理论效度)。
  • DRU-I效用值随DR严重程度加重而下降:非VTDR=0.87 vs VTDR=0.80(p=0.021)。
  • DRU-I效用值随较好眼视力损害加重而下降:无=0.84、轻度=0.78、中/重度=0.72(p=0.012)。

关键数值与推荐

  • DRU-I维度包括视觉症状、活动受限/移动、光线与眩光、社会情绪健康及不便程度,每项按无、一些或很多困难评级。
  • 非VTDR组DRU-I效用值为0.87,VTDR组为0.80(p=0.021)。
  • 较好眼无视力损害组DRU-I效用值为0.84,轻度组为0.78,中/重度组为0.72(p=0.012)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To validate a preference-based Diabetic Retinopathy Utility Index (DRU-I) using discrete choice experiment (DCE) methods and assess disutilities associated with vision-threatening DR (VTDR: severe non-proliferative DR, proliferative DR and clinically significant macular oedema) and associated vision impairment. METHODS: The DRU-I comprises five quality-of-life dimensions, including Visual symptoms, Activity limitation/mobility, Lighting and glare, Socio-emotional well-being and Inconvenience, each rated as no, some, or a lot of difficulty. The DRU-I was developed using a DCE comprising six blocks of nine choice sets which, alongside the EuroQoL-5D (EQ-5D-3L) and Vision and Quality of Life (VisQoL) utility instruments, were interviewer-administered to participants. To ensure the DRU-I was sensitive to severe disease, we oversampled patients with VTDR. Data were analysed using conditional logit regression. RESULTS: Of the 220 participants (mean±SD age 60.1±11.3 years; 70.9% men), 57 (29.1%) and 139 (70.9%) had non-VTDR and VTDR, respectively, while 157 (71.4%), 20 (9.4%) and 37 (17.3%) had no, mild or moderate/severe vision impairment, respectively. Regression coefficients for all dimensions were ordered as expected, with worsening levels in each dimension being less preferred (theoretical validity). DRU-I utilities decreased as DR severity (non-VTDR=0.87; VTDR=0.80; p=0.021) and better eye vision impairment (none=0.84; mild=0.78; moderate/severe=0.72; p=0.012) increased. DRU-I utilities had low (r=0.39) and moderate (r=0.58) correlation with EQ-5D and VisQoL utilities, respectively (convergent validity). DISCUSSION: The DRU-I can estimate utilities associated with vision-threatening DR and associated vision impairment. It has the potential to assess the cost-effectiveness of DR interventions from a patient perspective and inform policies on resource allocation relating to DR.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Fenwick EK, Bansback N, Gan ATL, et al. Validation of a novel diabetic retinopathy utility index using discrete choice experiments. Br J Ophthalmol. 2019. PMID: 31097442. doi:10.1136/bjophthalmol-2019-313899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。